Author information
1
Institute for Genomic Medicine, Columbia University, New York, New York.
2
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina.
3
Gilead Sciences, Inc., Foster City, California.
4
Divisions of Infectious Diseases and Hepatology/Gastroenterology, Department of Medicine, Johns Hopkins University, Baltimore, Maryl.
5
Duke Clinical Research Institute, Durham, North Carolina.
6
Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina.
Abstract
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.